ISAR BIOSCIENCE - Key Persons
Hans-Peter Holthoff stud ied chem istry in Würzburg and received his PhD in molecu lar genet ics in Kon stanz. From 2000 to 2007 he worked in the biotech com pany Pro Corde until its mer ger with Tri gen plc, Lon don as sci entific pro ject leader in the field of tar get val id a tion in car di ovas cu lar dis eases. From 2007 onwards he took over the sci entific man age ment first at Cor im mun GmbH which was sold to Janssen-CIL AG/ John son & John son in 2012 and later at advance COR GmbH until 2020. In addi tion to his activ it ies as a test man ager for the GLP area, Hans-Peter Holthoff was mainly act ive in the field of per son al ized dia gnostics and in clin ical drug devel op ment in the field of ath er o scler o sis and heart fail ure. Hans-Peter Holthoff joined ISAR Bioscience in 2021 as CTO.
Job Titles:
- Director of the Neurodegeneration Program
Miriam Christl meier stud ied bio logy at the Uni ver sity of Freiburg, focus ing on Neuro bi o logy and Immun o logy. Through out her 4 years of PhD she was work ing at research insti tutes in Ger many, the UK and Switzer land and pub lished her work in high impact journ als. After suc cess ful com ple tion of her dis ser ta tion and a short post-doc toral stay at the Depart ment of Bio medi cine in Basel, she joined the Depart ment of Prof. Chris tian Haass at the LMU Munich. Here, she focused her research on microglia cells and invest ig ated the func tion of lncRNAs in this context.
Miriam Christl meier joined ISAR Bioscience as one of the first mem bers in 2018 and was instru mental in set ting up the labor at ory and estab lish ing the neuro de gen er a tion pro gram. Since Feb ru ary, 2021 she is head ing the neuro de gen er a tion pro gram with a spe cial focus on microglia cells.
Horst Dom dey is one of the defin ing per son al it ies of the Ger man start-up and life sci ence scene. After study ing bio logy and chem istry in Erlan gen, his sci entific career took him to the Max Planck Insti tute for Bio chem istry in Mar tin sried for his PhD, as a post-doc toral fel low at ISREC in Epalinges/Lausanne, at the Uni ver sity of California/San Diego and at the Cal tech in Pas adena. He was a group leader at the Gene Cen ter and has been Pro fessor of Bio chem istry at the Uni ver sity of Munich since 1994. In 1998, he became Man aging Dir ector of BioM AG and in this capa city made the Munich region a cen ter for com pany start-ups in the life sci ences. From 1998 to 2008 he was also Sci entific Man aging Dir ector of the Innov a tion and Start-up Centre for Bio tech no logy (IZB) in Mar tin sried near Munich. Horst Dom dey is co-founder of sev eral bio tech no logy com pan ies. He is a mem ber of numer ous advis ory and coordin a tion com mit tees in Ger many and inter na tion ally. His sci entific interests lie in the field of RNA bio logy, but more gen er ally in the field of trans la tion, i.e. the trans fer of find ings from basic research into bio med ical applic a tions. Horst Dom dey was awar ded the Bav arian State Medal for spe cial ser vices to the Bav arian eco nomy and the Order Pro mer itis sci en tiae et litterarum.
Jörn Erselius has been Man aging Dir ector of Max Planck Innov a tion GmbH, the tech no logy trans fer insti tu tion of the Max Planck Soci ety, since the end of 2005. After com plet ing his doc tor ate in bio logy under Peter Gruss, he joined Max Planck Innov a tion GmbH (formerly Garch ing Innov a tion GmbH) in 1991 as Pat ent and License Man ager. He then estab lished the new Life Sci ences busi ness unit there. After com plet ing a part-time Mas ter of Busi ness Admin is tra tion (MBA) degree course, he was appoin ted head of the licens ing divi sion in early 2005. Jörn Erselius super vised numer ous com pany spin-offs from the Max Planck Soci ety (includ ing Evotec, Sci enion, Alnylam and Vaxxilon).
Jörn Erselius PhD Deputy Chair man; Man aging Dir ector Max Planck Innov a tion GmbH
Job Titles:
- CIO Cyclerion Former Member of the Board of Management of Bayer Health Care
Andreas Busch is one of the most dis tin guished research man agers in the phar ma ceut ical industry. After an aca demic career in physiology and phar ma co logy in Ger many and the USA, the phar macist moved to industry. From 1999 to 2004, he was Vice President/Global Head of Car di ovas cu lar Research at San ofi-Aventis in Frankfurt/Main, then until 2017 at Bayer Pharma as a mem ber of the Bayer Health Care Board of Man age ment and Exec ut ive Vice Pres id ent and Global Head Drug Dis cov ery. From 2018 to 2019 he was Head of R&D and CSO at Shire Phar ma ceut ic als and since 2019 he has been Chief Innov a tion Officer, Cyclerion Inc, Switzerland/USA. Andreas Busch has been Pro fessor of Phar ma co logy at the Uni ver sity of Frank furt since 2000. He has been and still is a mem ber of numer ous advis ory boards of research insti tu tions and com pan ies, includ ing Takeda as well as start-up com pan ies such as Omei cos and Ber lin Cures in Berlin.
Prof. Thomas Eschen ha gen MD Dir ector of the Insti tute of Phar ma co logy, Uni ver sity of Ham burg; Chair man of the Board DZHK
Job Titles:
- Expert
- Professor of Neurobiology, Institute for Stroke and Dementia Research, University of Munich
Dominik Paquet is an expert for induced pluri po tent stem cells, CRISPR/Cas gen ome engin eer ing and the applic a tion of these tech no lo gies for research on neuro de gen er at ive and neur ovas cu lar dis eases. He has been a Pro fessor at the Uni ver sity of Munich and mem ber of the Munich Cluster of Sys tems Neur o logy (SyN ergy) since 2016 and leads a research lab at the Insti tute for Stroke and Demen tia Research (ISD) of the Uni ver sity Hos pital in Munich. Dominik Paquet holds a degree in Bio logy from the Uni ver sity of Tübin gen and a doc tor ate in Bio chem istry and Phar ma co logy from the Uni ver sity of Munich. Pre vi ously, he worked for five years as a postdoc toral fel low with Marc Tessier-Lav igne at The Rock e feller Uni ver sity in New York, USA, where he pub lished sem inal stud ies on CRISPR/Cas gen ome engin eer ing and dis ease mod el ing of Alzheimer's and related demen tias in iPSCs.
Dr. Paquet received sev eral research awards includ ing the Inter na tional Leda-Hanin- and Verum-Awards for Alzheimer's Dis ease research, the Young Invest ig ator Award of the Uni versität Bay ern, the San ofi iAward Europe, as well as fel low ships from the Elite Net work of Bav aria, Ger man Academy of Sci ences Leo pold ina and The New York Stem Cell Foundation.
Job Titles:
- Member of the Foundation Board
Martin Lohse is Chair man of ISAR Bioscience. He stud ied medi cine and philo sophy at the Uni ver sit ies of Göt tin gen, Lon don and Paris and did research at the Uni ver sit ies of Bonn, Heidel berg, Durham (NC, USA) and at the Gene Cen ter Munich. Since 1993 he has been Pro fessor of Phar ma co logy at the Uni ver sity of Würzburg, where he foun ded and dir ec ted the Rudolf Virchow Cen ter. From 2016 to 2019 he was dir ector of the Max Del brück Cen ter in Ber lin. He is also hon or ary pro fessor of bio chem istry at the Free Uni ver sity Berlin.
Martin Lohse has received numer ous national and inter na tional awards, includ ing the Leib niz prize, the highest dis tinc tion in Ger man sci ence, and the Fed eral and Bav arian Orders of merit. He is a mem ber of many academies of sci ence and was Vice-Pres id ent of the National Academy of Sci ences Leo pold ina from 2009 to 2019. Since 2019 he has been Pres id ent of the Soci ety of Ger man Nat ural Sci ent ists and Phys i cians (GDNÄ).
Martin Lohse is one of the founders of the bio tech no logy com pan ies Pro Corde, Cor Im mun and advance COR. His sci entific interests include drug research and in par tic u lar the invest ig a tion of recept ors as tar gets for novel drugs for dis eases of the car di ovas cu lar and nervous systems.
Job Titles:
- Chief Scientific Officer, Medicine
Martin Ungerer is a phys i cian and car di olo gist. He stud ied at the Uni ver sity of Munich and spent an aca demic year in France. After a post-doc toral stay at the Max Planck Insti tute for Biochemistry/Gene Cen ter, Mar tin sried, he com pleted his spe cial ist train ing as an intern ist and car di olo gist at the Klinikum rechts der Isar and Ger man Heart Cen ter of the TU Munich, where he also did his habil it a tion. From 2000 onwards, he foun ded biotech com pan ies together with col leagues and man aged them as Chief Scientific/Medical Officer and Man aging Dir ector: Pro Corde GmbH until its mer ger with Tri gen plc, Lon don, Cor im mun GmbH, which was sold to Janssen-CIL AG/ John son & John son in 2012, and advance COR GmbH. In these com pan ies he was respons ible for the trans la tion of research pro jects from pre clin ical stud ies to clin ical phase I and II stud ies in the fields of car di ovas cu lar dis eases and immun o logy. Martin Ungerer has also con tinu ously been work ing in patient care on a part-time basis and is a pro fessor of medi cine at the Uni ver sity of Würzburg.
Thomas Eschen ha gen is a med ical doc tor and phar ma co lo gist and has been Dir ector of the Insti tute of Phar ma co logy at the Uni ver sity of Ham burg since 2002. His spe ci al ity is car di ovas cu lar research, where he is one of the lead ing inter na tional sci ent ists, par tic u larly in the field of strength en ing and regen er at ing the heart. Since its found a tion in 2011, Thomas Eschen ha gen has been Chair man of the Board of the Ger man Centre for Car di ovas cu lar Research (DZHK), and since 2019 he has been Pres id ent of the Inter na tional Soci ety for Heart Research. He is a mem ber of the board of the Ger man Found a tion for Heart Research and has been Asso ci ate Editor of Cir cu la tion, one of the lead ing car di ovas cu lar journ als, since 2016. Thomas Eschen ha gen is a mem ber of the Academy of Sci ences in Göt tin gen, the Leo pold ina and the Aca demia Euro paea and has been awar ded fund ing by the European Research Coun cil, ERC